Executive Team

Dr. Ruhong Jiang, Ph.D.

Dr. Ruhong Jiang, Ph.D., Co-founder, President and CEO

Most recently, Dr. Jiang has served as General Manager of China Operations at MicuRx Pharmaceuticals (a California-based novel drug discovery company). Dr. Jiang received a Ph.D. degree in the U.S. He has more than twenty-five years of experience in life science research, and more than 12 years of product development and management experience in several biotech companies. Dr. Jiang led a team which launched one of the first personalized medicine diagnostic tests, FamilionTM, in the US market. Dr. Jiang has developed an extensive network in the biotech industry and academic institutions both in the U.S. and China. Dr. Jiang is also a member of our Executive Team.

Dr. Ruby Yanru Chen-Tsai

Dr. Ruby Yanru Chen-Tsai, Ph.D., Co-founder and CSO

Dr. Chen-Tsai received her PhD from Cornell University. She has been working with embryonic stem cells and genetic animal models for over 18 years. Prior to joining ASC, Dr. Chen-Tsai worked at Stanford University for 19 years as the Director of the Transgenic Research Center and Associate Director of the Stanford Cancer Institute, overseeing nine research support labs. Her lab at Stanford University successfully isolated many novel embryonic stem cell lines using proprietary technologies. Her research at Stanford focused on genome engineering in Parkinson patient-specific iPS cell lines and their differentiation to dopaminergic neurons. Dr. Chen-Tsai is also a leading expert in disease animal models including transgenic and knockout mouse models. She is a co-inventor of the TARGATT™ technology. Dr. Chen-Tsai is an author of many scientific papers and holder of several patents.

Applied StemCell, Michael Clearly

Dr. Michael Cleary, MD, Co-founder / Associate Chair, Department of Pathology, Stanford University

Associate Chair for Experimental Pathology, Stanford University School of Medicine and Director of Pediatric Cancer Biology, Stanford University School of Medicine, Dr. Cleary received his MD from the University of Cincinnati Medicine (1981). His laboratory studies the molecular pathogenesis of cancer. They have discovered several genes that are damaged by chromosomal translocations in human leukemias. His group is currently investigating the normal functions of these genes and their contributions to cancer employing a variety of experimental approaches that include biochemical techniques and in vitro cellular transformation assays as well as genetic analyses using transgenic and knockout mouse models.

Board Members

Dr. Ruhong Jiang, Ph.D.

Dr. Ruhong Jiang, Ph.D., Co-founder, President and CEO

Most recently, Dr. Jiang has served as General Manager of China Operations at MicuRx Pharmaceuticals (a California-based novel drug discovery company). Dr. Jiang received a Ph.D. degree in the U.S. He has more than twenty-five years of experience in life science research, and more than 12 years of product development and management experience in several biotech companies. Dr. Jiang led a team which launched one of the first personalized medicine diagnostic tests, FamilionTM, in the US market. Dr. Jiang has developed an extensive network in the biotech industry and academic institutions both in the U.S. and China. Dr. Jiang is also a member of our Executive Team.

 

Dr. Jerry Xiao, Ph.D., Managing Director, HerMed Capital

Doctor in Pharmacology, member of Bio China Advisor Committee, Post Doc in Rochester University, during which he co-founded a pharmaceutical company with Dr. Paul Okunieff, and received STTR support from the US government. He was the deputy chief of the IPO team for the Fosun Pharma Listing on the Hong Kong Exchange. He was the deputy director of Fosun Pharmaceutical Technological Center, in charge of the evaluation of new technology, R&D and investment, he reviewed more than 150 projects per annum. He also served as a board member of Fochon Pharma (new drug development platform of Fosun), Henlius (Biosimilar) and Dalian Wanchun (new drug), helping with the financing and technology transfer.

 

Dr. Guo-Liang Yu, Ph.D., CEO and President, Epitomics, Inc.

Biotechnologist and entrepreneur Dr. Yu has more than 12 years of experience in genomics and 24 years of experience in life sciences research. Before cofounding Epitomics, Dr. Yu was Senior Vice-President of Research and Development at Mendel Biotechnology, Inc. He is a co-inventor and co-author of more than 100 patents and scientific articles.

Business Advisors

Dr. Dean Tsao, PhD, Chairman and CEO, PlexBio, Inc.

Dr. Tsao is an accomplished scientist and a successful entrepreneur with an excellent track record of launching and leading new companies to grow into successful businesses including Zymed Laboratories, Genemed Biotechnologies, Genemed systhesis, Zytogene and PlexBio.

Dr. Nancy Chang, PhD, President at Apex Enterprise

Dr. Nancy Chang was Senior Managing Director at Orbimed Advisors, LLC. Prior to Orbimed, she co-founded Tanox, Inc. and served as Chairman and CEO from the company’s beginnings in 1986 until its acquisition by Genentech in 2007. She has received numerous awards for her professional accomplishments and serves on the board of many companies.

Dr. James J. Zhu, Ph.D., JD, MBA, Partner at Jun He Law Offices

Prior to joining Jun He, James was a partner at Perkins Coie's Los Angeles Office, and the Managing Partner of Perkins Coie's Beijing Office.  James was President & CEO for China United On-line, an internet company in Beijing.  James was a co-founder and General Counsel of GanTech international, a venture capital-backed start-up in Silicon Valley. James worked as a research scientist at Merck & Co. in early 1990s. 

 

Applied StemCell, Shengjiang

Dr. Shengjiang Liu, Ph.D., Principal Scientist and Department Head, Bayer HealthCare

Shengjiang is the Head and principle scientist of Pathogen Safety in Bayer Biological Development. He is also an investor of early stage venture in high-tech and biotech innovation.  He was a cofounder and the president of Abmaxis Inc. (acquired by Merck & Co., Inc. in 2006) in antibody engineering and development.  He was the group leader and scientist of Genentech (Roche). He discovered rabbit hemorrhagic disease virus (RHDV), rabbit calicivirus, in mid 80s. Dr. Liu received his Ph.D. in biochemistry from Kansas State University and post-doctoral training with Dr. Arthur Kornberg (1993-1996) in Stanford University.

Grace Tian, Co-founder and CEO, Biochain Institute, Inc.

Grace is a successful Biotechnology entrepreneur with an excellent track record. She co-founded Biochain Research Institute, BioChain (Beijing) Science & Technology. Inc. and Beijing Modern Gaoda Biotechnology Co.

Scientific Advisors

Applied StemCell, Dr. Michele Calos

Dr. Michele Calos, Ph.D., Professor of Genetics, Stanford University

Dr. Calos is a Professor in the Department of Genetics, Stanford University School of Medicine, Stanford, CA, where she has served as a tenured faculty member since 1987.  She received her Ph.D. in Biochemistry and Molecular Biology from the laboratory of Nobel laureate Prof. Walter Gilbert at Harvard University and pursued postdoctoral training at the University of Geneva in Switzerland.  Her research focuses on sequence-specific genetic engineering as a tool for generating transgenic cell lines and organisms and for advancing gene and stem cell therapies for diseases such as muscular dystrophy.  Dr. Calos’ research career encompasses the development and use of several cutting-edge plasmid vector systems for molecular biology applications, such as shuttle vectors, Epstein-Barr virus plasmids, autonomous replication systems for mammalian cells, and integrating vector systems.  Her laboratory pioneered the use of the site-specific FC31 phage integrase to modify mammalian cells and, in collaboration with Applied StemCell’s Chief Scientific Officer Dr. Ruby Yanru Chen-Tsai and Stanford Professor Dr. Liqun Luo, to engineer transgenic mice.  Additionally, Dr. Calos’ experience includes serving as the Vice President of the American Society of Gene and Cell Therapy, as well as service on the Advisory Committee of the US FDA for Cell, Tissue, and Gene Therapy, grant review committees for the NIH, NSF, and various international agencies, and editorial work for numerous scientific journals.

Scientific-advisor-Dr-Hong-Wu

Dr. Hong Wu, MD and Ph.D., Dean of the School of Life Sciences, Peking University (PKU)

Hong Wu is a Professor of Molecular and Medical Pharmacology at UCLA School of Medicine, and a member of UCLA Molecular Biology Institute and Jonsson Comprehensive Cancer Center. She is the Director of the UCLA Molecular Genetics Technology Center and the co-director of Cancer Stem Cell Program area of the newly formed UCLA Institute for Stem Cell Biology and Medicine. Dr. Wu received her M.D. degree from Beijing Medical College, China, and her Ph.D. degree in Biological Chemistry from Harvard Medical School, working with Rudolf Jaenisch at the Whitehead Institute for Biomedical Research. She was a Damon Runyon-Walter Winchell postdoctoral fellow with Harvey Lodish at the Whitehead Institute for Biomedical Research, MIT. Her laboratory studies the signal transduction pathways controlled by the PTEN tumor suppressor gene, using various genetically engineered animal tumor models.

Applied StemCell, Michael Clearly

Dr. Michael Cleary, MD, Co-founder / Associate Chair, Department of Pathology, Stanford University

Associate Chair for Experimental Pathology, Stanford University School of Medicine and Director of Pediatric Cancer Biology, Stanford University School of Medicine, Dr. Cleary received his MD from the University of Cincinnati Medicine (1981). His laboratory studies the molecular pathogenesis of cancer. They have discovered several genes that are damaged by chromosomal translocations in human leukemias. His group is currently investigating the normal functions of these genes and their contributions to cancer employing a variety of experimental approaches that include biochemical techniques and in vitro cellular transformation assays as well as genetic analyses using transgenic and knockout mouse models.

Dr. Qilong Ying, Ph.D., MD, Associate Professor, University of Southern California

Qi-Long Ying is Associate Professor of Cell and Neurobiology at the Eli and Edythe Broad Center for Regenerative Medicine and Stem Cell Research at USC. He obtained his Ph.D in molecular biology in 1995 and completed his postdoctoral training in Austin Smith’s group at the University of Edinburgh in 2006. His current research focuses on understanding embryonic stem cell self-renewal and generating transgenic rat models using the embryonic stem cell-based gene-targeting technology.